Japan's Astellas shows nearly 50% gain in Q1 even as sales drag on price revisions

First quarter financial year core operating profit for Tokyo-based Astellas Pharma reached ¥67.1 billion, up a tad more than 49% even as overall sales dipped on reimbursement price revisions in Japan.

However, the company said in a release that sales of Xtandi (enzalutamide) grew and aided the bottom line along with the transfer of the global dermatology business in April, part of a $727 million deal with Danish specialty product firm LEO last year.

"We are pleased with our solid performance and ability to achieve sustainable growth through increasing sales of Xtandi … and overall (bladder) treatments, new product introductions and focused investment in innovation and strengthening our base,” said Yoshihiko Hatanaka, president and CEO of Astellas.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Overall sales, however, fell nearly 6% in the first quarter ended June 30, compared to the same period a year ago, to ¥337.8 billion.

- here's the release

Related Articles:
British watchdogs suspend Astellas UK after investigations, audits, and a crackdown from Japanese HQ
Drug price cuts in Japan sink in though details sparse
Japan's Astellas eyed to buy Kaketsuken's vaccine business
Astellas' Xtandi under pressure as U.S. lawmakers push for generic swap
Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas

Read more on

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.